SKB445 / Sichuan Kelun Pharma - LARVOL DELTA

Phase 1 clinical stage (The Manila Times) - "SKB107 (RDC)[2]: The Phase 1 study is ongoing; SKB535/MK-6204 (novel ADC with potential FIC target): The Phase 1 clinical trial for SKB535 is ongoing in China; SKB445 (novel ADC with potential FIC target): The Phase 1 clinical trials for SKB445 is ongoing in China; SKB105/CR-003 (ITGB6 ADC): In January 2026, an IND application was approved by the CDE of NMPA for the treatment of advanced solid tumor. A Phase 1/2 trial is ongoing in China."

Trial status • Bone Cancer • Cervical Cancer • Colorectal Cancer • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Non Small Cell Lung Cancer • Pancreatic Cancer • Squamous Cell Carcinoma of Head and Neck

SKB518, SKB535/MK-6204 and SKB445: (PRNewswire) - "Novel ADC drugs with potential FIC targets. The Phase 2 clinical trial for SKB518 and the Phase 1 clinical trials for SKB535 and SKB445 are ongoing in China. The Company has entered into a license and collaboration agreement with MSD to develop SKB535."

Licensing / partnership • Trial status • Solid Tumor

SKB445 for Injection in Solid Tumors (clinicaltrials.gov) - P1 | N=126 | Recruiting | Sponsor: Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Solid Tumor

SKB445 for Injection in Solid Tumors (clinicaltrials.gov) - P1 | N=126 | Not yet recruiting | Sponsor: Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.

New P1 trial • Oncology • Solid Tumor

Kelun-Biotech’s novel ADC drug SKB445 receives NMPA approval to treat advanced solid tumours (Pharmabiz) - "Sichuan Kelun-Biotech Biopharmaceutical...announced that the company has received a clinical trial notice approving the investigational new drug application for the innovative drug SKB445 developed by the company from the Center for Drug Evaluation of the National Medical Products Administration....SKB445 is a novel ADC drug with proprietary intellectual property rights developed by the Company based on the biological characteristics of the target and using the technology of the OptiDC platform, which has demonstrated promising efficacy and safety window in preclinical studies and is intended to be used for the treatment of advanced solid tumours."

New trial • Solid Tumor